Summary:
In participants with type 1 diabetes (T1D), MBX-2982, a GPR119 agonist significantly augmented glucagon counterregulatory responses to hypoglycemia compared to placebo, though it was associated with nausea in some participants.
| PICO | Description |
|---|---|
| Population | Adults aged 20–60 years with type 1 diabetes (T1D). |
| Intervention | MBX-2982, a GPR119 agonist. |
| Comparison | Placebo administered in a double-masked, crossover design. |
| Outcome | MBX-2982 significantly augmented glucagon counterregulatory responses to experimental hypoglycemia versus placebo. Some participants reported nausea, but no severe adverse events were observed. |
Source: Anika Bilal, et al. “A Randomized Controlled, Double-Masked, Crossover Study of a GPR119 Agonist on Glucagon Counterregulation During Hypoglycemia in Type 1 Diabetes.” Diabetes Research and Clinical Practice. Read article here.
